1.
|
Phase: Phase III, Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: R08096M, VEL-1-08-DK-002, 26866138MMY2063, NCT00861250
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MMY3024, NCT00984828
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT: 2005-001628-35, EBMT-CLWP: 42206611, NCT00256776
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 61 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR006127, 26866138MMY3013, NCT00416208
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 0 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR006124, NCT00416273
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NMSG 15/05, EudraCT No: 2005-002756-18, NCT00417911
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C05009, NCT00507416
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1A05, E1A05, NCT00522392
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: UARK 2006-66, NCT00572169
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: 2006-15, NCT00574080
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0777, S0777, NCT00644228
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 25009, 59306670 7R01CA115399, NCT00670631
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NMSG 17/07, EudraCT no. 2007-001292-11, NCT00602511
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 26866138-LYM-3002, NCT00722137
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 26866138 MMY 3021, NCT00722566
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LCC-HM05/7287, HM05/7287, EU-20873, ISRCTN60123120, EudraCT-2006-005890-24, NCT00747877
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_525, MK0683-088, NCT00773747
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR015247, NCT00813150
|
|
20.
|
Phase: Phase III
Type: Natural history/Epidemiology
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Version 1.1, NCT00872352
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Perifosine 339, NCT01002248
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0306106, MILLENNIUM-MM2003, NCT00084747
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0321, N0321, NCT00093756
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2333, PHI 0241, NCT00209248
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 4K-05-1, NCT00184015
|
